A study testing whether a GLP-1 medicine, semaglutide, can help people lose weight.

Who can join: Children and teens 12 to 18, have obesity, BMI 35+.
What you take: semaglutide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The full study runs about 7.4 years; your own time in it is usually shorter.
What you get: Many clinical trials pay for the study medication and the study visits. Some also pay for travel. Ask the study team what this one covers before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Phase 3Sponsor Children's Hospital Los AngelesDrug semaglutideClass GLP-1 RASites 1 USEnrollment target 150

What this study is for

Primary condition: Pediatric Obesity. Also studied in: Metabolic and Bariatric Surgery, Semaglutide.

Full scientific study title: Early Re-Initiation of Semaglutide Post Sleeve Gastrectomy in Youth.

Who can join

Age12 to 18SexAnyBMI35 or higher

Children and teens 12 to 18, have obesity, BMI 35+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

ages 12 to 18 years
Tanner stage 3 or higher
severe obesity (defined as a BMI greater than 35 kg/m2 or BMI ≥140% of the 95th percentile)
currently undergoing primary surgical weight loss through the pediatric bariatric surgery pathway at Children's Hospital Los Angeles
be willing to have blood collected before and after surgical procedure at defined points

Key exclusion criteria

have a previous diagnosis of type 1 diabetes
taking any medications known to influence body composition or prevent weight loss or promote weight gain (e.g. prednisone)
have been diagnosed with syndromes or diseases that may influence the postoperative course (e.g., Cushing syndrome, Down syndrome, Prader Willi Syndrome)
have significant comorbid medical conditions necessitating frequent hospitalization that may require interruption of medications and/or that would make early re-initiation of semaglutide unsafe due to the other medical comorbidities
refuse to comply with eligibility criteria.

Where this trial runs

This trial has 1 sites across 1 state. Site contacts are listed for reference. They are not screening through this trial right now.

California1 site

Children's Hospital Los Angeles
Los Angeles, California

Follow this trial

We email you if NCT06934655 changes status, adds new sites in your state, or if a similar trial opens for the same condition. No spam, opt out any time.

Timeline

Scheduled start: June 1, 2026. Expected completion: November 1, 2033. Last updated on ClinicalTrials.gov: March 17, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked August 21, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site · LinkedIn · Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.